The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats

European Neuropsychopharmacology

Volumn 21, Issue 7, 2011, Pages 526-531

  Holly, Elizabeth N ^a   Ebrecht, Bree ^a   Prus, Adam J ^a  

^a NORTHERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Catalepsy; Clozapine; Conditioned avoidance response; Haloperidol; Neurotensin; PD149163

Indexed keywords

CLOZAPINE; DEXAMPHETAMINE; HALOPERIDOL; NEUROTENSIN RECEPTOR ANTAGONIST; PD 149163; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONDITIONED AVOIDANCE RESPONDING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG SCREENING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; VALIDATION PROCESS;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CENTRAL NERVOUS SYSTEM STIMULANTS; CLOZAPINE; CONDITIONING, CLASSICAL; DEXTROAMPHETAMINE; DRUG EVALUATION, PRECLINICAL; HALOPERIDOL; MALE; NEUROTENSIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN;

EID: 79959253715     PISSN: 0924977X     EISSN: 0924977X     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.12.004     Document Type: Article

References (38)

1. Adams M.R., Brandon E.P., Chartoff E.H., Idzerda R.L., Dorsa D.M., McKnight G.S. Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice. Proc Natl Acad Sci USA 1997, 94:12157-12161.
2. Ahlenius S., Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: a comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacol Biochem Behav 1986, 24:1409-1415.
3. Bartoszyk G.D., Roos C., Ziegler H. 5-HT1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 1996, 35:1645-1646.
4. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol Rev 2001, 53:453-486.
5. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur J Pharmacol 2001, 426:73-76.
6. Boules M., Liang Y., Briody S., Miura T., Fauq I., Oliveros A., Wilson M., Khaniyev S., Williams K., Li Z., Qi Y., Katovich M., Richelson E. NT79: a novel neurotensin analog with selective behavioral effects. Brain Res 2010, 1308:35-46.
7. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res 2000, 856:48-54.
8. Elliott P.J., Nemeroff C.B. Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine-induced locomotor activity. Neurosci Lett 1986, 68:239-244.
9. Feifel D., Reza T.L., Wustrow D.J., Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther 1999, 288:710-713.
10. Feifel D., Melendez G., Shilling P.D. A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology 2003, 28:651-653.
11. Feifel D., Melendez G., Shilling P.D. Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 2004, 29:731-738.
12. Feifel D., Melendez G., Murray R.J., Tina Tran D.N., Rullan M.A., Shilling P.D. The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacolog Berl 2008, 200:197-203.
13. Feifel D., Mexal S., Melendez G., Liu P.Y., Goldenberg J.R., Shilling P.D. The Brattleboro rat displays a natural deficit in social discrimination that is restored by clozapine and a neurotensin analog. Neuropsychopharmacology 2009, 34:2011-2018.
14. Feifel D., Goldenberg J., Melendez G., Shilling P.D. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology 2010, 58:195-198.
15. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002, 14:47-57.
16. Goldstein J.M. The new generation of antipsychotic drugs: how atypical are they?. Int J Neuropsychopharmacol 2000, 3:339-349.
17. Hadden M.K., Orwig K.S., Kokko K.P., Mazella J., Dix T.A. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology 2005, 49:1149-1159.
18. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999, 286:105-107.
19. Hertel P., Byskov L., Didriksen M., Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur J Pharmacol 2001, 422:77-81.
20. Hertel P., Olsen C.K., Arnt J. Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. Eur J Pharmacol 2002, 439:107-111.
21. Jacobson S.M., Prus A.J. Evaluation of the effects of alpha2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats. Behav Pharmacol 2010, 21:654-659.
22. Jolas T., Aghajanian G.K. Neurotensin and the serotonergic system. Prog Neurobiol 1997, 52:455-468.
23. Luttinger D., Nemeroff C.B., Prange A.J. The effects of neuropeptides on discrete-trial conditioned avoidance responding. Brain Res 1982, 237:183-192.
24. Mark Evers B. Neurotensin and growth of normal and neoplastic tissues. Peptides 2006, 27:2424-2433.
25. Millan M.J., Schreiber R., Dekeyne A., Rivet J.-M., Bervoets K., Mavridis M., Sebban C., Maurel-Remy S., Newman-Tancredi A., Spedding M., Muller O., Lavielle G., Brocco M. S 16924 ((R)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 1998, 286:1356-1373.
26. National Research Council (1996) Guide for laboratory animal facilities and care. National Research Council, National Research Council.
27. Olsen C.K., Kreilgaard M., Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav 2006, 84:259-265.
28. Petrie K.A., Bubser M., Casey C.D., Davis M.D., Roth B.L., Deutch A.Y. The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology 2004, 29:1878-1888.
29. Sarhan S., Hitchcock J.M., Grauffel C.A., Wettstein J.G. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 1997, 18:1223-1227.
30. Shibata K., Yamada K., Furukawa T. Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice. Psychopharmacolog Berl 1987, 91:288-292.
31. Shilling P.D., Feifel D. The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle. Pharmacol Biochem Behav 2008, 90:748-752.
32. Shilling P.D., Richelson E., Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav Brain Res 2003, 143:7-14.
33. Shilling P.D., Melendez G., Priebe K., Richelson E., Feifel D. Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist. Psychopharmacolog Berl 2004, 175:353-359.
34. Snijders R., Kramarcy N.R., Hurd R.W., Nemeroff C.B., Dunn A.J. Neurotensin induces catalepsy in mice. Neuropharmacology 1982, 21:465-468.
35. Wadenberg M.L., Hicks P.B. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics?. Neurosci Biobehav Rev 1999, 23:851-862.
36. Wadenberg M.L., Young K.A., Trompler R.A., Zavodny R.A., Richter T.J., Hicks P.B. A novel computer-controlled conditioned avoidance apparatus for rats. J. Pharmacol. Toxicol. Methods 1998, 38:211-215.
37. Wadenberg M.G., Browning J.L., Young K.A., Hicks P.B. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 2001, 68:363-370.
38. Wustrow D.J., Davis M.D., Akunne H.C., Corbin A.E., Wiley J.N., Wise L.D., Heffner T.G. Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity. Bioorg Med Chem Lett 1995, 5:997-1002.